A small, early trial of a vaccine that mobilizes the immune system to battle advanced kidney cancers appears successful, researchers report.

A new vaccine for kidney cancer shows excellent preliminary results. All patients on the trial had no evidence of cancer three years after the pioneering treatment.

In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

Scientists at the Dana-Farber Cancer Institute and elsewhere developed the vaccine, which is designed to prevent advanced cases of kidney cancer from returning. Since the trial patients received the vaccine roughly three years ago,